Related Experiment Videos
[Left ventricular hypertrophy--an important, often unrecognized risk factor]
Insights
Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular events in hypertensive patients. Studies suggest that reducing LVH may decrease cardiovascular risk, pending clinical trial confirmation.
Area of Science:
- Cardiology
- Hypertension Research
- Echocardiography
Context:
- Left ventricular hypertrophy (LVH) identified via echocardiography is a potent cardiovascular risk factor in both general and hypertensive populations.
- While commonly linked to hypertension, LVH develops in less than half of hypertensive individuals.
- Factors implicated in LVH development include insulin resistance, endothelial dysfunction, increased blood viscosity, reduced arterial compliance, and elevated angiotensin-converting enzyme activity.
Purpose:
- To review the established link between left ventricular hypertrophy (LVH) and cardiovascular events.
- To explore the multifactorial etiology of LVH in hypertensive patients.
- To discuss the potential benefits of LVH regression on cardiovascular risk.
Summary:
- Epidemiological data confirm left ventricular hypertrophy (LVH) as a major predictor of cardiovascular events.
- The development of LVH in hypertension is multifactorial, involving metabolic and hemodynamic factors.
- Observational studies indicate that regression of LVH may reduce cardiovascular risk, though prospective trials are ongoing.
Impact:
- Highlights LVH as a critical target for cardiovascular risk reduction strategies in hypertension.
- Underscores the need for further clinical trials to validate the benefits of LVH regression.
- Informs clinical practice regarding the assessment and management of hypertensive patients at risk for cardiovascular events.
Abstract:
Epidemiological studies both in the general population and in series of hypertensive patients have shown the presence of left ventricular hypertrophy (LVH), as determined by echocardiography, to be a powerful risk factor for cardiovascular events. Although LVH is generally associated with hypertension, less than half of hypertensive patients develop LVH. Insulin resistance, endothelial dysfunction, increased blood viscosity, decreased arterial compliance, and increased angiotensin-converting enzyme activity have all been associated with the development of LVH. Although findings in observational studies suggest LVH regression to have a beneficial effect in terms of decreased cardiovascular risk, confirmation of this awaits the results of prospective clinical trials currently being carried out.